Neoantigen Peptides Manufacturing Market Size, Share & Trends Analysis Report By Scale of Operations (Research/Preclinical, Clinical, Commercial), By End-Users (Pharmaceutical/Vaccine developers companies, Contract Research Organizations, Academic and research institutes, Region And Segment Forecasts, 2025-2034

Global Neoantigen Peptides Manufacturing Market Size is valued at USD 1.4 Billion in 2024 and is predicted to reach USD 6.3 Billion by the year 2034 at a 16.4% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

• The increasing prevalence of cancer as well as other chronic illnesses is a major factor driving the growth of the neoantigen peptides manufacturing market.
• Rapid progress in next-generation sequencing, bioinformatics, and machine learning is driving the growth of the neoantigen peptides manufacturing market.
• North America dominated the market and accounted for a global revenue share in 2024.
• Higher costs of designing and developing personalized cancer therapeutics are a challenge for the neoantigen peptides manufacturing market.

Neoantigens are newly generated peptides that are capable of inducing tumour-specific T cell recognition. These are created through somatic mutations. Researchers and physicians have recently used next-generation sequencing technology to detect neoantigens and develop tailored cancer immunotherapies. Neoantigens are short peptides derived from tumour-specific somatic mutations. These peptides bind to HLA (Human Leucocyte Antigen) molecule to be recognized by T-Cell Receptors (TCRs), which further activate the immune system for specific cancer cells. In manufacturing neoantigen-based vaccines, personalized neoantigen peptides are synthesized, which helps induce the T-cell population. This new type of immunotherapy can produce a strong and specific immune response and draw out stable therapeutic effects. As a result, personalized neoantigen peptide vaccines are designed to train a patient's immune system to target and kill tumour cells. Hence they are used to develop vaccines and immunotherapies against cancer cells. These significant neoantigens can control tumour outgrowth and felicitate cellular transformation.

Synthetic peptides are a recognized model of cancer vaccine delivery, but creating the peptides for each patient rapidly and inexpensively remains difficult. The rising number of clinical trials, the growth in cancer and chronic illness cases, and the necessity for long-term therapy for these diseases are all prominent market factors for Neoantigen peptide synthesis. Furthermore, advances in biotechnology research will help researchers better understand individualized neoantigen peptides. Increased external investment in cancer drug research and development, on the other hand, drives the market upward. On the other hand, costly designing and development of personalized cancer therapeutics and delayed clinical trials due to the COVID-19 impact will restrain the market.

Competitive Landscape

Some of The Key Players in The Neoantigen Peptides Manufacturing Market:

• CPC Scientific Inc
• Polypeptide group
• Genscript Biotech
• Kaneka Eurogentec S.A.
• Vivitide
• Almac
• BCN Peptides
• Creative Peptides
• Pepscan
• Provepharm
• Creosalus
• Gyros Protein Technologies
• AnaSpec
• Other Prominent Players

Market Segmentation

The Neoantigen Peptides Manufacturing Market is segmented into the Scale of operations, end-users, and region. The scope of operation segment comprises research/preclinical, clinical, and commercial. The market is segmented into pharmaceutical/vaccine developer companies, contract research organizations (CRO), and academic & research institutes by end-users. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The North American market can witness rapid growth during the forecast period (2020-2030) due to the well-established healthcare infrastructure, growing research regarding Peptide synthesis, and the rising government efforts to develop personalized vaccines.

Recent Developments:

• In June 2022, CPC Scientific Inc., a prominent global CRDMO specializing in peptides, made a substantial investment in a state-of-the-art manufacturing facility for peptide APIs, bolstering job opportunities in Rocklin, California.

The Neoantigen Peptides Manufacturing Market Report Scope